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The Consolidated Standards of Reporting Trials (CONSORT) Statement was published in 1996, and first introduced
to China in 2001. Although CONSORT has been widely accepted in high-quality international journals, we still need
to have more investigation on how many Chinese journals have adopted the CONSORT Statement, and whether
the quality of reporting has improved. A systematic search of the “Instructions to authors” in all Chinese medical
journals in China Academic Journals (CAJ) Full-text Database was conducted up to February 2012 and only 7 journals
officially listed the requirements of the CONSORT Statement. The research articles about randomized controlled trials
(RCTs) published in 2002, 2004, 2006, 2008, and 2010 from journals which had specifically adopted the CONSORT
Statement, and from 30 top journals based on the Chinese Science Citation Index (CSCI) 2011 as the control group,
were identified. The quality of both cohorts of articles was assessed using the revised CONSORT Checklist and Jadad
scale. A total of 1221 Chinese medical journals was identified. Only seven journals stated clearly in the “Instructions to
authors” that authors should adopt the CONSORT requirement in the clinical trial paper. None of these journals is
among the control group in the CSCI 2011. In the selected years, a total of 171 articles from 7 journals which had
adopted CONSORT and 232 articles in the control were identified as including RCT trials. The average scores according
to the revised CONSORT Checklist were 29.47 for the CONSORT-adopting journals and 25.57 for the control group;
while the average scores based on the Jadad scale were 2.53 for CONSORT-adopting journals and 1.97 for the control
group. Few journals among Chinese medical journals have adopted the CONSORT Statement. The overall quality of
RCT reports in the 7 journals which have adopted CONSORT was better than those in the top 30 journals which have
not adopteded CONSORT. The quality of RCT reports in Chinese journals needs further improvement, and the
CONSORT Statement could be a very helpful guideline.
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Due to the unsatisfactory situation of randomized con-
trolled trial (RCT) reporting, in 1993, 30 experts met in
Ottawa, Canada with the aim of developing a new scale
to assess the quality of RCT reports [1]. After merging
with another group of experts from Chicago (USA), the
Consolidated Standards of Reporting Trials (CONSORT)
Statement was first published in 1996 [2]. Previous stud-
ies have shown that CONSORT did improve the quality
of reports of RCTs [3, 4]. A revised CONSORT State-
ment was published in 2001 to refine this standard [5],
and a further revision (CONSORT 2010 Statement) was* Correspondence: bianzxiang@gmail.com
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creativecommons.org/publicdomain/zero/1.0/published in 8 journals simultaneously in 2010 [6]. By 4
August 2011, 458 core international peer-reviewed med-
ical journals on PubMed had endorsed the CONSORT
Statement [6]. In China, a previous survey was con-
ducted to assess the endorsement of the CONSORT
Statement by high-impact medical journals in 2012 and
found that only 6 journals mentioned “CONSORT” in
their “Instructions to authors” [7].
Before 2007, the quality of RCT reports in China was
not good. In an RCT quality evaluation based on the
CONSORT 2001 Statement [8], 142 published RCTs
from 2004 to 2007 in 5 leading Chinese medical journals
were assessed and it was found that only a very small
number of CONSORT items was reported clearly in all
included trials. Another report, which included 307
RCTs conducted in China and published in 2004, cameicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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thors have pointed out that improving trial reporting
quality was necessary if not also urgent [8, 9]. For the
improvement of reporting quality, different parties, such
as researchers, clinicians, journalists, funding agency,
policy makers and drug companies, should work to-
gether to make sure that each paper meets certain mini-
mum standards, thus ensuring that the public can access
to pertinent trial information. In this circumstance, jour-
nalists, as the “door keepers” of publication, play a cru-
cial role. From this point of view, the CONSORT
Statement, providing specific and comprehensive guide-
lines for trial reporting, could be used by different par-
ties as rules for good publication. Therefore, adoption of
this standard becomes a very crucial step in informing
the authors how to design, carry out and report trials of
the best quality.
By 25 February 2012, 1221 medical journals were
found in the database, and this number is expected to
increase in the future. Among these journals, there are a
few international peer-reviewed journals; for these jour-
nals, the low quality of the papers is always an issue for
discussion [8, 9]. In this study, we firstly conducted a
systematic search of the “Instructions to authors” in all
Chinese medical journals to identify the journals adopt-
ing the CONSORT Statement. Then we compared these
journals’ RCT report quality with a control group (top
thirty highest-impact journals in China). Through these
process we examined all the medical journals in China
to explore how many of them had adopted the CON-
SORT Statement, how they used it, and the influence of
the CONSORT Statement on the quality of papers pub-
lished in these journals, to analyze the current applica-
tion status of the CONSORT Statement in China and




Selection of Chinese medical journals
China Academic Journals (CAJ) Full-text Database is the
most comprehensive, full-text database of Chinese jour-
nals in the world [10] (accessed from http://www.cnki.
net). This database contains all the medical journals in
China, both in English and in Chinese. We examined all
the medical journals listed under the subtitle of “Journal
Navigation” in the database [11].
Collecting “Instructions to authors”
“Instructions to authors” statements of each journal
comprise the basic requirements for articles to be con-
sidered and/or accepted for publication in the journal.
Therefore, “Instructions to authors” statements of each
journal were collected and by checking these statements,it could be determined whether or not the journal en-
dorsed the CONSORT Statement. The searching pro-
cesses were as follows: firstly, the homepage of each
journal was searched under the “Journal Navigation” in
the CAJ database, then “Instructions to authors” was
checked through the journal’s online website. Secondly,
we searched the key words “author,” “information” and/
or “instruction” and these were further investigated if no
formal item of “Instructions to authors” could be found.
Again, if no information for authors was found, the
“Instructions to authors” statement for a journal was
searched in the www.google.com, as a substitution.
Determining which journals adopted the CONSORT
Statement
After downloading the “Instructions to authors,” eight
students scrutinized the CONSORT Statement adoption
in two individual groups. One group is for the journals
which were identified as adopting the CONSORT State-
ment, and the other group is for the journals without any
available “Instructions to authors.” TJ Song conducted a
third check to confirm the results.
Journal selection for quality assessment of RCT
In order to assess the quality of reporting, trial articles
were collected. The journals which had adopted the
CONSORT Statement were selected as targets. The 30
top medical journals with the highest impact factor (IF)
in the Chinese Science Citation Index (CSCI) 2011 were
selected as the controls. There is no overlap between the
top 30 journals in the CSCI system and the 7 journals
adopting the CONSORT Statement; in other words,
none of the top CSCI journals have adopted CONSORT.
Search strategy for RCT reports
Inclusion criteria Based on the aim of this study, we
would like to search all the RCT reports related to medi-
cation intervention. The following criteria for inclusion
were set as follows. All trials had to meet all criteria:
i. Trials with interventions in human beings
ii. Trials with chemical agents, biological agents or
Traditional Chinese Medicine (TCM) herbs or with
acupuncture or electroacupuncture as interventions
iii. Trials with the aim of testing the therapeutic effects
of interventions










10.7 OR 8 OR 9
11.6 AND 11
Exclusion criteria Articles reporting trials with nutri-
tional therapy (oral feeding, iodine, and/or food) were
excluded. Trials comparing the effects of surgery, psy-
chological treatment, and/or physical therapies were also
excluded.
Targeted RCT articles Three databases were searched
for articles meeting the inclusion criteria published in
the selected journals. Articles written in Chinese were
downloaded from the China Journal Net Database
(http://www.cnki.net/) and Chinese Science and Tech-
nology Documents Database (VIP) (http://www.cqvip.
com/). The search strategy was set. In order to limit the
working load, it was decided, arbitrarily, to select only
articles published in even numbered years; in other
words, only articles published in 2002, 2004, 2006, 2008,
and 2010 were counted. Duplicates from these two data-
bases were removed. For articles written in English,Fig. 1 Flow chart of article search listsPubMed (http://www.ncbi.nlm.nih.gov/pubmed/) was
searched with the same limits regarding the publica-
tion year, i.e., 2002, 2004, 2006, 2008 and 2010. A flow
chart of article search lists is presented in Fig. 1. Two
reviewers (TJ Song and HF Leng) independently assessed
the RCT articles.Assessment of RCT report quality
CONSORT Checklist The scoring scale was set based
on the 2010 CONSORT Checklist in which there are 25
items [12]. In order to ensure that all items were in-
cluded in the final trial report, each item with multiple
contents was broken down such that each sub-item was
counted separately, as listed in Table 1. Each extracted
article was assessed using this scoring system. If the item
was included in the RCT report, one point was awarded,
and the total point score represented the quality of that
clinical report. For quality assessment, firstly all re-
viewers underwent training in evaluating RCTs using the
revised CONSORT Checklist, which including the state-
ment and Explanation and Elaboration (E&E). During
the assessment, discrepancies were resolved by consen-
sus, or decided by ZX Bian. The score for each item was
either 0 or 1 depending on whether the authors had re-
ported it. The maximum score was 84. The scores for
Table 1 Revised 2010 Consolidated Standards of Reporting Trials (CONSORT) Checklist
Section/Topic Number Description
Title and Abstract 1 Identification as a randomized trial in the title
2 Has an abstract
3 Has a structured summary
4 Summary including trial design
5 Summary including methods
6 Summary including results
7 Summary including conclusions
Introduction
Background and objectives 8 Scientific background
9 Explanation of rationale
10 Specific objectives or hypotheses
Methods
Trial design 11 Description of trial design (such as parallel, factorial)
12 Description including allocation ratio
13 Important changes to methods after trial commencement (such as eligibility criteria)
14 Reasons for changes to methods after trial commencement
Participants 15 Eligibility criteria for participants
16 Settings and locations where the data were collected
Intervention 17 States precise details of the interventions intended for each group about how to conduct the
administration which could allow replication
18 States precise details of the interventions intended for each group about when to conduct the
administration which could allow replication
Outcomes 19 Defined what is the primary outcome measures
20 Completely defined how the primary outcome measures were assessed
21 Completely defined when the primary outcome measures were assessed
22 Defined what is the secondary outcome measures
23 Completely defined how the secondary outcome measures were assessed
24 Completely defined when the secondary outcome measures were assessed
25 Any changes to trial outcomes after the trial commenced
26 Reasons of changes to trial outcomes after trial commenced
Sample size 27 How sample size was determined
28 When applicable, any interim analyses
29 Explanation of the interim analyses
30 When applicable, any interim stopping guidelines
31 Explanation of stopping guidelines relative with interim analyses.
Randomization
Sequence generation 32 Method to generate the random allocation sequence
33 Types of randomization
34 Details of any restriction for randomization (such as blocking and block size)
Allocation concealment mechanism 35 Mechanism used to implement the random allocation sequence (such as sequentially numbered
containers)
36 Describes any steps taken to concealed the sequence until interventions were assigned
Implementation 37 States who generated the allocation sequence
38 States who enrolled participants?
39 States who assigned participants to interventions (their trail groups)
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Table 1 Revised 2010 Consolidated Standards of Reporting Trials (CONSORT) Checklist (Continued)
Blinding 40 States that the trial is blinded or open.
41 States how the trial is blinded
42 States who was blinded after assignment to interventions (for example, participants,
care providers, those assessing outcomes)
43 If relevant, description of the similarity of interventions
Statistical methods 44 Defines the statistical methods used in the trail
45 Defines statistical methods used to compare groups for primary outcomes
46 Defines statistical methods used to compare groups for secondary outcomes
47 Methods for additional analyses, such as subgroup analyses and adjusted analyses
Results
Participant flow (a diagram is strongly
recommended)
48 For each group, the numbers of participants who were randomly assigned
49 For each group, the numbers of participants who received intended treatment
50 For each group, the numbers of participants who were analyzed for the primary outcome
51 For each group, losses and exclusions after randomization
52 Reasons for losses and exclusions after randomization
Recruitment 53 Define the periods of recruitment
54 Define the specific dates of recruitment
55 Define the periods of follow-up
56 Define the specific dates of follow-up
57 Why the trial ended or was stopped
Baseline data 58 A table showing the baseline demographic and clinical characteristics for each group
Numbers analyzed 59 Actual number of participants in each group
60 States whether the analysis was by original assigned groups
Outcomes and estimation 61 Summary of results for each group with primary outcomes
62 Estimates effect size for primary outcomes
63 Estimates precision of effect size (95 % confidence interval) for primary outcomes
64 Summary of results for each group with secondary outcomes
65 Estimates effect size for secondary outcomes
66 Estimates precision of effect size (95 % confidence interval) for secondary outcomes
67 For binary outcomes, presentation of both absolute and relative effect sizes is recommended
Ancillary analyses 68 Results of any other analyses performed, distinguishing prespecified from exploratory
69 Results of subgroup analyses performed, distinguishing prespecified from exploratory
70 Results of adjusted analyses performed, distinguishing prespecified from exploratory
Harms 71 All important harms or unintended effects in each group
Discussion
Limitations 72 Trial limitations
73 Addressing sources of potential bias
74 Addressing sources of imprecision
75 If relevant, addressing source of multiplicity of analyses
Generalizability 76 Generalizability (external validity or applicability) of the trial findings
Interpretation 77 Interpretation of results
78 Balancing benefits and harms
79 Considering other relevant evidence relating with the results
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Table 1 Revised 2010 Consolidated Standards of Reporting Trials (CONSORT) Checklist (Continued)
Other Information
Registration 80 Registration number
81 Name of trial registry
Protocol 82 Where the full trial protocol can be accessed, if available
Funding 83 Sources of funding and other support (such as supply of drugs)
84 Role of funders
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was conducted under the categories of Title (1), Abstract
(2–7), Introduction (8–10), Methods (11–47), Results
(48–71), Discussion (72–79), and Other Information
(80–84).Jadad scale The Jadad scale is a 5-point scale for evalu-
ating the quality of randomized trials in which 3 points
or more indicates superior quality [13, 14]. It is com-
monly used to evaluate RCT quality [15]. The Jadad
scale includes 5 items: (1) description of randomization;
(2) adequacy and appropriateness of randomization
method; (3) description of single-blindness or double-
blindness; (4) whether assessors are blinded to treatment
conditions; and (5) description of withdrawals and drop
outs. The score for each of the first 3 items was either 1
or 0 depending on whether the authors had reported it
or not, respectively. The score for each of the last 2
items ranged from −1 to 1 (according to the explanation
of the Jadad scale, −1 meant an inappropriate method
description [16]). The maximum Jadad score was five.
The scores for the five items were assessed by two inde-
pendent persons, and the scores were added together.
An average score was calculated.
Initially, they received the “Revised CONSORT State-
ment for Reporting Randomized Trials: Explanation and
Elaboration” document, which provides the meaning
and rationale for each checklist item and examples of
good reporting practice. All reviewers received training
in research methodology for basic clinical research
methodology and evaluation of quality of RCT re-
ports using Jadad scale provided by our taught course
“Epidemiology and Critical Appraisal”, including the
studied CONSORT Statement 2010. Besides, the as-
sessment was blinded.Data analysis
Data for descriptive statistics were analyzed using
Microsoft Excel 2007 (Microsoft Inc., Redmond, WA,
USA). For comparisons of reporting quality between the
target group (seven journals) and control group (top
thirty journals), an average score was calculated for each
publication year studied.Results
Journals endorsing the CONSORT Statement until 2011
After searching for “Instructions to authors” on the CJN
website and in its printed publication, 1140 official “In-
structions to authors” were found in total. Further, 57
unofficial materials from websites other than the home-
pages of journals were collected. Also, 24 journals’ “In-
structions to authors” could not be found.
After checking the content of “Instructions to authors”,
only seven journals officially listed the requirements of the
CONSORT Statement. These journals were as follows:
Chinese Journal of Cancer Biotherapy, Chinese Medical
Journal (CMJ, published in English), Hepatobiliary &
Pancreatic Diseases International (HPDI, published in
English), Chinese Journal of Evidence-Based Medicine,
Journal of Chinese Integrative Medicine, Shanghai
Archives of Psychiatry, and Chinese Journal of Evidence-
Based Pediatrics.
Article extraction
Based on CSCI 2011, 30 top journals ranked by IF were
chosen: these are listed in Table 2. After searching
PubMed, VIP and CMJ (up to 19 January 2012), 1680 ar-
ticles were extracted. Based on the exclusion criteria of
this study, 403 articles were finally selected for further
analysis, with 232 articles from the control group, and
171 articles from journals adopting the CONSORT
Statement.
Quality of articles
RCT quality assessed with the revised CONSORT
2010 Checklist As shown in Fig. 2, the quality of RCT
articles has increased from 2002–2010. For the top 30
journals, the scores for the 232 articles has slightly in-
creased from 24.93 ± 3.51 in 2002, 23.78 ± 5.69 in 2004,
26.02 ± 5.93 in 2006 and 25.43 ± 5.50 in 2008 to 26.35 ±
5.94 in 2010. For the 7 journals which had endorsed the
CONSORT Statement, the average score of article qual-
ity in 2002 was 25.46 ± 4.01, which is slightly higher
than that of 24.93 ± 3.51 for articles from the top 30
journals, and the scores in the following years are also
higher than that of the top 30 journals, with 27.97 ±
3.56 in 2004, 30.40 ± 5.16 in 2006, 29.22 ± 5.28 in 2008
and 31.29 ± 6.9 in 2010. The scores from the seven




1 Chinese Journal of Interventional Imaging and
Therapy
1.4875
2 Chinese Pharmacological Bulletin 0.8357
3 Chinese Herbal Medicine 0.6875
4 Journal of Pharmaceutical Sciences 0.6674
5 World Journal of Gastroenterology (WJG) 0.6479
6 The Journal of Immunology 0.5564
7 Chinese Journal of Endocrinology and metabolism 0.5356
8 Chinese Journal of Endemiology 0.5337
9 Chinese Journal of Pathophysiology 0.5159
10 Chinese Journal of Otology 0.5116
11 Chinese Journal of Virology 0.5058
12 Chinese Journal of Medical Imaging Technology 0.5041
13 Chinese Journal of Microsurgery 0.4856
14 Microbiology 0.4444
15 Acupuncture Research 0.3864
16 Chinese Critical Care Medicine 0.3758
17 China Journal of Chinese Materia Medica 0.3655
18 Acta Physiologica Sinica 0.3598
19 Chinese Journal of Pharmaceutical Analysis 0.3458
20 Chinese Journal of Neurology 0.3380
21 Chinese Journal of Preventive Medicine 0.3290
22 Chinese Journal of Radiation Oncology 0.3265
23 Acta Pharmacologica Sinica 0.3204
24 Chinese Traditional Patent Medicine 0.3193
25 Journal of Third Military Medical University 0.3100
26 Chinese Journal of Ultrasonography 0.3052
27 Chinese Journal of Nervous and Mental Diseases 0.3043
28 Chinese Journal of Reparative and Reconstructive
Surgery
0.2962
29 Chinese Journal of Burns 0.2953
30 Chinese Journal of Antibiotics 0.2953
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trol group.
Furthermore, sub-item analysis showed that the report-
ing ratio for Abstracts and Introductions is high, with
more than 80 % of CONSORT 2010’s suggested content
being reported in both target and control groups of jour-
nals; however, the reporting rates of content in other sub-
items were all below 50 %. The details were elaborated as
follows:
Title and abstract Among 171 articles from the target
group of journals, 68 (40 %) identified their studies asRCTs in the title. Most articles provided abstracts; 5 did
not (3 in 2004, 1 in 2006, and 1 in 2010). In contrast,
only 8 % (19 out of 232) of the control group journals’
articles identified their studies as RCTs in the title, and
13 articles (1 in 2004, 6 in 2006, 4 in 2008, and 2 in
2010) did not have an abstract.
Introduction The average scores of “Introduction” for 7
journals and the control group were 2.76 and 2.69, re-
spectively. Every article from the 7 endorsing journals
included an introduction, while 6 articles (2 from 2006,
3 from 2008, 1 from 2010) from the control group did
not contain one.
Methods No article in any cohort showed a comprehen-
sive method flow. Only 16.96 % (29 out of 171) of arti-
cles from the 7 endorsing journals and 7.33 % (17 out of
232) of articles from the control group clearly identified
the type of randomization. Only 16.37 % (28 out of 171)
of articles from the 7 journals and 6.47 % (15 out of 232)
of articles from the control group gave a description of
the allocation ratio. No article in either cohort of jour-
nals reported any important changes to methods after
trial commencement. Nearly all the articles provided
precise information about the eligibility criteria for par-
ticipants; however, only 80.12 % (137 out of 171) of arti-
cles from the 7 endorsing journals and 50 % (116 out of
232) of articles from the control group provided precise
details about the settings and locations where the data
were collected.
For “Intervention,” the intervention delivery method
was clearly presented, and 84.22 % (144 out of 171) of
articles from the 7 endorsing journals and 95.26 % (221
out of 232) from the control group reported this infor-
mation clearly. But, only 35.09 % (60 out of 171) of arti-
cles from the 7 endorsing journals and 34.91 % (81 out
of 232) of articles form the control group provided pre-
cise time information.
For “Outcomes,” very few articles definitely stated the
primary and secondary outcomes in their trial. Only
19.88 % (34 out of 171) of articles from the 7 endorsing
journals and 9.05 % (21 out of 232) of articles from the
control group mentioned it. Further, some articles
neglected to report the assessment time and measure-
ment for outcomes. No article reported any changes of
trial outcome index.
For “Sample Size,” only 20 (15 from the 7 endorsing
journals and 5 from the control group) articles reported
how this was determined. No article gave any informa-
tion about the interim analyses. Only 2 articles, from the
Chinese Journal of Evidence-Based Medicine [17, 18],
gave the interim stopping guideline of the whole trial.
For “Randomization,” “Allocation Concealment,”
“Sequence Generation” and “Implementation,” no article
Fig. 2 Randomized controlled trial (RCT) quality assessed with the revised Consolidated Standards of Reporting Trials (CONSORT) 2010 Checklist.
For the top 30 journals, the scores for the 232 articles have slightly increased, and for the 7 journals which had endorsed the CONSORT
Statement, the average score of article quality is slightly higher than that of articles from the top 30 journals
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over, in 33.92 % (58 out of 171) of articles from the 7 en-
dorsing journals and 48.28 % (112 out of 232) of articles
from the control group, they only mentioned “randomly”
to represent all these items.
For “Blinding,” only 32.75 % (56 out of 17z1) of arti-
cles from the 7 endorsing journals and 21.12 % (49 out
of 232) of articles from the control group stated whether
the trial was blinded or open. No article got full marks
in this area. In all 403 articles, only 46 described how to
conduct blinding.
For “Statistical Methods,” 96.53 % (389 out of total
403) of articles defined the statistical methods used in
the trial. Nevertheless, only 8 articles (5 from the 7 en-
dorsing journals and 3 from the control group) pointed
out the statistical methods used in comparing primary
or secondary outcomes. Four articles (two from the
seven endorsing journals and two from the control
group) pointed out the statistical methods used in add-
itional analysis.
Results No significant superiority was found for articles
from the 7 endorsing journals for “Results,” with the
average score 8.36, comparing with 7.03 for articles from
the control group. For “Participant flow,” almost all the
articles (98 % from the 7 endorsing journals and 97.84 %
from the control group) reported the numbers of partici-
pants who were randomly assigned. However, the per-
centage of articles that reported the numbers of
participants who had received intended treatment was
less: 22 % (37 out of 171) for the 7 endorsing journals
and 9 % (20 out of 232) for the control group. Fifty per-
cent (86 out of 171) of articles from the 7 endorsing
journals and 31.03 % (72 out of 232) of the articles fromthe control group clearly reported the number of losses
and exclusions after randomization. However, only 42 %
(44 out of 171) of articles from the 7 endorsing journals
and 21.98 % (51 out of 232) of articles from the control
group gave the reasons. For “Recruitment,” as high as
77.78 % (133 out of 171) of articles from the 7 endorsing
journals and 68.97 % (160 out of 232) of articles from
the control group defined the periods of recruitment.
Among them, 9 out of 133 articles and 17 out of 160 ar-
ticles neglected the specific month. Around half the arti-
cles (51.46 % from the 7 endorsing journals and 48.28 %
from the control group) reported the follow-up periods.
Only ten articles (two from the seven endorsing journals
and eight from the control group) stated the specific
dates of follow-up. Seven (five from the seven endorsing
journals and two from the control group) articles in total
reported the reason why the trial ended or was stopped.
For “Baseline Data,” 38.01 % (65 out of 171) of articles
from the 7 endorsing journals and 34.48 % (80 out of
232) of articles from the control group showed the base-
line demographic and clinical characteristics for each
group. For “Number Analysis,” 24.56 % (42 out of 171)
of articles from the 7 endorsing journals and 10.34 % (24
out of 232) of articles from the control group explained
how the analysis was performed, either “intention-to-
treat” or “per protocol.”
For “Outcomes and Estimation items,” if the articles
identified what the primary and secondary outcomes
were, almost all of them would summarize the results
separately. Very limited numbers of articles estimated
the effect size between groups. No articles published in
2002 estimated effect size for both primary and second-
ary outcomes together with precision. Less than 5 % of
articles for both the 7 endorsing journals and the control
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precision of effect size (62, 63, 65, and 66). No binary
outcome was presented of both absolute and relative ef-
fect size. For “Ancillary Analyses,” only 2 articles (1 from
the 7 endorsing journal group and 1 from the control
group) published in 2010 mentioned other analyses
which were performed, distinguishing prespecified from
exploratory. The article from the control group also
mentioned the adjusted analyses which were performed,
also distinguishing prespecified from exploratory. For
“Harms,” 92.98 % (159 out of 171) articles of the 7 en-
dorsing journals reported important harms or unin-
tended effects in each group, whereas, only 37.5 % of
articles from the control group reported it.
Discussion For “Limitations,” no article clearly sepa-
rated potential bias with imprecision, though some arti-
cles (32.75 % for the 7 endorsing journals and 13.36 %
for the control group) mentioned that their trials had
limitations. No relevant source of multiplicity analyses
was addressed for all the articles. For “Generalizability,”
only one fifth of articles (29.82 % for the 7 endorsing
journals and 18.97 % for the control group) mentioned
it. For “Interpretation,” almost all articles (400 out of
403) interpreted the results except 3 articles (1 from the
7 endorsing journal group and 2 from the control
group). The majority of articles (71.35 % for the 7 en-
dorsing journals and 64.22 % for the control group) con-
sidered other relevant evidence relating with the results.
Other information Nearly half the articles (41.52 % for
the 7 endorsing journals and 43.10 % for the control
group) provided sources of funding and other support,
but only 4 articles (3 from the 7 endorsing journals and
1 from the control group) identified the role of funders.
Only seven articles (five from the seven endorsing jour-
nals and two from the control group) mentioned trialFig. 3 The score assessed by the Jadad scale. The tendency of the Jadad s
Reporting Trials (CONSORT) scoreregistration number, six of them gave the name of trial
registry (four from the seven endorsing journals and two
from the control group). No article mentioned where
the full trial protocol could be accessed.
The score assessed by the Jadad scale The range of the
Jadad score for all the articles was between 0 and 5. As
shown in Fig. 3, the tendency of the Jadad score was in
accord with that of CONSORT score. For the 7 journals
which had endorsed the CONSORT Statement, the aver-
age score for the 171 articles increased from 2.04 in
2002, 2.2 in 2004, 2.68 in 2006, and 2.29 in 2008 to 2.96
in 2010. For the control group, the average score for the
232 articles has been slightly increased from 1.94 in
2002, 1.78 in 2004, 2.02 in 2006 and 1.94 in 2008 to 2.14
in 2010.
For item 1 of Jadad scale, all the articles got a full
mark. Although some articles did not identify the name
of the trial design, the use of words such as “randomly,”
“random,” and “randomization” could be found in all the
articles. For item 2 of Jadad scale, only about one fifth of
the RCTs (28.07 % from the 7 endorsing journal group
versus 17.67 % from the control group) were designed as
double-blinded trials. For item 3 of Jadad scale half the
articles (53.80 %) from the 7 endorsing journals reported
the drop-out situation, whereas, only 29.74 % of articles
from the control group reported it. For item 4 of Jadad
scale although articles reporting the method for
randomization from both cohort journals could reach
about 50 %, a total of 8 articles reported a wrong
method according to the definition of inappropriate
randomization method from the Jadad scale. For item
5 of Jadad scale, about 10 % of articles (15.20 % from
the 7 endorsing journals and 7.76 % from the control
group) reported the double-blind method. No appar-
ently inappropriate double-blind method was found for
this item.core was in accord with that of the Consolidated Standards of
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The fact that China publishes 1221 medical journals in
total indicates the large scale of its medical journal out-
put. Clearly, some journals published “Instructions to
authors” in the Announcement section and updated
these frequently; but some journals had not updated
their “Instructions to authors,” for more than 10 years.
Further, the content of “Instructions to authors” varies
considerably; the simplest one is one sentence only,
which amounts to “key theme, clear statement, accurate
evidence and standard writing.” It is evident that “In-
structions to authors” constitutes a bridge between the
authors and journalists, and the journal in question can
tell the authors what kind of research articles they want
and what kind of standard the article should meet. The
current situation regarding “Instructions to authors”
may reflect the observation that not all journals could be
improved upon the quality of the articles published in
their journals Besides, most of the journals only men-
tioned the CONSORT Statement and did not point out
the version of CONSORT Statement. In these instances,
perhaps the translation of the CONSORT Statement was
conducted by the editors without any verification
process. On the other hand, even the journals that had
adopted CONSORT 2010 were those that routinely pro-
vide information to authors about good reporting so this
was already happening before the translation of that
statement.
CONSORT Statements were first published in 1996
but not formally introduced to China until they ap-
peared in 2 articles published in October 2001 [17, 18];
formal full translation of the CONSORT Statement en-
dorsement by the CONSORT Group was in October
2007 [6]. However, based on our search results, only 7
Chinese medical journals had introduced the CONSORT
Statement in their “Instructions to authors” up to Febru-
ary 2012. These figures imply that CONSORT has been
largely ignored in China since its publication.
Strong evidence, however, has shown that CONSORT
has improved the quality of reporting [3, 4]. Results
from evaluating papers using the CONSORT Checklist
and the Jadad scale showed that the quality of RCT re-
ports published in Chinese medical journals has gener-
ally improved in the past ten years; even so, the level of
quality is worrisome. The average scores of the articles
from two cohort journals were low. This result is con-
sistent with that from other researchers [8, 19–21]. En-
couragingly, the quality of articles published in the 7
journals which have adopted the CONSORT Statement
is higher than that of the top 30 journals. These data
suggest that CONSORT endorsement contributes to this
slight difference and is also consistent with studies of
journals published in other parts of the world. For ex-
ample, a review in 2001 showed that the quality of RCTsfrom Western journals which adopted CONSORT (BMJ,
JAMA and The Lancet) is higher than that from The
New England Journal of Medicine, which did not adopt
CONSORT at that time [3]. Another report published in
2006 also proved that CONSORT guideline could im-
prove RCT quality [22] and Chinese researchers now ac-
knowledge that adoption of CONSORT leads to an
improvement in report quality [8, 19].
On the other hand, the quality of RCTs from the target
cohort of journals is not as high as we expected. The
real, or absolute, quality of them was unsatisfactory. The
same conclusion has been drawn from other reports. A
typical example is an article from the Journal of Chinese
Integrative Medicine [23], which clearly stated that
CONSORT requirements were followed, but its CON-
SORT Checklist score is only 38 (45.24 %). CONSORT
endorsement is only one step toward improving journal
article quality. Other factors, such as the training back-
ground of researchers, the original design of the trial, re-
quirements of journal, etc., are highly related to the final
quality of reporting. Improving the design, execution
and reporting of RCTs is a systematic task with multiple
aspects. Because the CONSORT Statement addresses all
of these aspects, we recommend that it should be imple-
mented in full as a reporting standard.
Limitations
The systematic search strategy was set first to find arti-
cles meeting the inclusion criteria. The article search
was limited to two databases (CJN and VIP). Although
these two databases cover most medical journals in
China, there is a possibility that we missed some data.
The likelihood that the results of using CONSORT are
associated with better quality of clinical trials’ outcomes
is also discussed in order to spread and recommend this
practice among Chinese medical journal editors.
Conclusion
Relatively few medical journals in China have adopted
the CONSORT Statement. After assessing RCTs using
both the detailed CONSORT Checklist and the Jadad
Checklist, results showed that the overall quality of re-
ports of RCTs in the 7 journals which had adopted the
CONSORT Statement was better than those in the top
30 journals. Nevertheless, the overall quality of RCT re-
ports in journals of China, though increasing, was poor.
Recommendations
The CONSORT Statement is a valuable effort by re-
searchers to standardize the reporting of trials. Results
prove that this statement really helps improve RCT trial
design, conducting and reporting. For this reason, we
highly recommended that: 1) all journals should present
clear and concrete “Instructions to authors” in readily
Song et al. Trials  (2015) 16:243 Page 11 of 11accessible ways; and 2) each medical journal in China
should adopt the CONSORT Statement.
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